Copeptin: Pathophysiology and potential clinical impact

Advances in Medical Sciences

Volumn 60, Issue 2, 2015, Pages 335-341

  Łukaszyk, Ewelina ^a   Małyszko, Jolanta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic heart failure; Chronic kidney disease; Copeptin; Vasopressin

Indexed keywords

ARGIPRESSIN; COPEPTIN; VASOPRESSIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ACUTE HEART INFARCTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; DIABETES INSIPIDUS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASES; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; KIDNEY DISEASE; LUNG DISEASE; METABOLIC SYNDROME X; NEUROHYPOPHYSIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PROGNOSIS; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; METABOLISM;

ANIMALS; ARGININE VASOPRESSIN; BIOMARKERS; GLYCOPEPTIDES; HEART FAILURE; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942324059     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2015.07.002     Document Type: Review

References (79)

1. R. Acher, J. Chauvet, and Y. Rouille Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport J Mol Neurosci 18 2002 223 228
2. C.L. Holmes, D.W. Landry, and J.T. Granton Science review: vasopressin and the cardiovascular system part 1 -receptor physiology Crit Care 7 2003 427 434
3. C.L. Holmes, D.W. Landry, and J.T. Granton Science review: vasopressin and the cardiovascular system part 2 - clinical physiology Crit Care 8 2004 15 23
4. F.M. de Bree, and J.P. Burbach Structure-function relationships of the vasopressin prohormone domains Cell Mol Neurobiol 18 1998 173 191
5. D.G. Bichet, M.F. Arthus, J.N. Barjon, M. Lonergan, and C. Kortas Human platelet fraction arginine-vasopressin. Potential physiological role J Clin Invest 79 1987 881 887
6. D.G. Bichet, C. Kortas, B. Mettauer, C. Manzini, J. Marc-Aurèle, J.L. Rouleau, and et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure Kidney Int 29 1986 1188 1196
7. D.A. Holwerda A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization Eur J Biochem 28 1972 334 339
8. N.G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
9. N.G. Morgenthaler, J. Struck, S. Jochberger, and M.W. Dunser Copeptin: clinical use of a new biomarker Trends Endocrinol Metab 19 2008 43 49
10. G. Szinnai, N.G. Morgenthaler, K. Berneis, J. Struck, B. Müller, U. Keller, and et al. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects J Clin Endocrinol Metab 92 2007 3973 3978
11. R. Roussel, L. Fezeu, M. Marre, G. Velho, F. Fumeron, P. Jungers, and et al. Comparison between copeptin and vasopressin in the population from the community and in people with chronic kidney disease J Clin Endocrinol Metab 99 2014 4656 4663
12. M. Katan, N. Morgenthaler, I. Widmer, J.J. Puder, C. König, B. Müller, and et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level Neuro Endocrinol Lett 29 2008 341 346
13. C.H. Nickel, R. Bingisser, and N.G. Morgenthaler The role of copeptin as a diagnostic and prognostic biomarker for the risk stratification in emergency department BMC Med 10 2012 7
14. K. Hanaoka, and W.B. Guggino cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells J Am Soc Nephrol 11 2000 1179 1187
15. E. Meijer, W.E. Boertien, R. Zietse, and R.T. Gansevoort Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease Kidney Blood Press Res 34 2011 235 244
16. L. Dobsa, and K.C. Edozien Copeptin and its potential role in diagnosis and prognosis of various diseases Biochem Med 23 2013 172 190
17. W.E. Boertien, E. Meijer, J. Li, M.A. van Dijk, T.J. Rabelink, M.H. Breuning, and et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort Am J Kidney Dis 61 2013 420 429
18. W.E. Boertien, E. Meijer, D. Zittema, M.A. van Dijk, T.J. Rabelink, M.H. Breuning, and et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease Nephrol Dial Transplant 27 2012 4131 4137
19. D. Zittema, E. van den Berg, E. Meijer, W.E. Boertien, A.C. Muller Kobold, and et al. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patient Clin J Am Soc Nephrol 9 2014 1553 1562
20. J. Małyszko, E. Koc-Zórawska, P. Koźmiński, J.S. Małyszko, M. Zórawski, and M. Mys̈liwiec Copeptin in hemodialyzed patients Nefrol Dial Pol 14 2010 182 184
21. J. Malyszko, P. Przybyłowski, E. Koc-Zórawska, N. Iaina-Levin, J. Sadowski, M. Mysliwiec, and et al. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients Transplant Proc 42 2010 4259 4262
22. S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, N.G. Morgenthaler, and et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stage of the disease J Am Coll Cardiol 52 2008 266
23. E. Meijer, S. Bakker, N. Halbesma, P.E. de Jong, J. Struck, and R.T. Gansevoort Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort Kidney Int 77 2010 29 36
24. S. Enhörning, L. Bankir, N. Bouby, J. Struck, B. Hedblad, M. Persson, and et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort Int J Obes 37 2013 598 603
25. B. Ponte, M. Pruijm, D. Ackermann, P. Vuistiner, I. Guessous, G. Ehret, and et al. Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study J Am Soc Nephrol 26 2015 1415 1425
26. C. Schrimpf, H.J. Gillmann, B. Sahlmann, A. Meinders, J. Larmann, M. Wilhelmi, and et al. Renal function interferes with copeptin in prediction of major adverse cardiac events in patients undergoing vascular surgery PLOS ONE 10 4 2015
27. M. Mockel, and J. Searle Copeptin - marker of acute myocardial infarction Curr Atheroscler Rep 16 2014 421
28. T. Reichlin, W. Hochholzer, C. Stelzig, K. Laule, H. Freidank, N.G. Morgenthaler, and et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction J Am Coll Cardiol 54 2009 60 68
29. K. Yalta, T. Yalta, N. Sivri, and E. Yetkin Copeptin and cardiovascular disease: a review of a novel neurohormone Int J Cardiol 167 5 2013 1750 1759 10.1016/j.ijcard.2012.12.039
30. M.J. Lipinski, R.O. Escárcega, and F. D'Ascenzo A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction Am J Cardiol 113 2014 1581 1591
31. M. Mockel, J. Searle, C. Hamm, A. Slagman, S. Blankenberg, K. Huber, and et al. Early discharge using single cardiac troponin and copeptin test in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study Eur Heart J 36 2015 369 376
32. S.J. Reinstadler, G. Klug, H.J. Feistritzer, B. Metzler, and J. Mair Copeptin testing in acute myocardial infarction: ready for routine use? Dis Markers 2015 2015 614145 10.1155/2015/614145
33. K. Wildi, C. Zellweger, R. Twerenbold, C. Jaeger, T. Reichlin, P. Haaf, and et al. Incremental value of copeptin to highly sensitive cardiac troponin I for rapid rule-out of myocardial infarction Int J Cardiol 190 2015 170 176
34. H. Ede, S. Karaçavuş, A.Y. Göçmen, B. Yaylak, S. Akkaya, B. AçIkgöz, and et al. Serum copeptin level can be helpful biomarker in evaluation of myocardial perfusion scintigraphy results Cardiol J 2015 10.5603/CJ.a2015.0036
35. N.A. Marston, K.S. Shah, C. Mueller, S.X. Neath, R.H. Christenson, J. McCord, and et al. Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial Emerg Med J 2015 10.1136/emermed-2015-204692 pii: emermed-2015-204692
36. U. Alehagen, U. Dahlström, J.F. Rehfeld, and J.P. Goetze Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure JAMA 305 2011 2088 2095
37. B. Stoiser, D. Mörtl, M. Hülsmann, R. Berger, J. Struck, N.G. Morgenthaler, and et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure Eur J Clin Invest 36 2006 771 778
38. S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, N.G. Morgenthaler, and et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease J Am Coll Cardiol 52 2008 266 272
39. A.A. Voors, S. von Haehling, S.D. Anker, H.L. Hillege, J. Struck, O. Hartmann, and et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study Eur Heart J 30 2009 1187 1194
40. J. Malyszko, H. Bachorzewska-Gajewska, K. Golabek, M. Zalewska-Adamiec, and S. Dobrzycki Copeptin and kidney function in patients with chronic heart failure Exp Clin Cardiol 20 2014 145 156
41. X. Li, X.C. Yang, Q.M. Sun, X.D. Chen, and Y.C. Li Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease Chin Med J 126 2013 823 827
42. E. Tenderenda-Banasiuk, A. Wasilewska, R. Filonowicz, U. Jakubowska, and M. Waszkiewicz-Stojda Serum copeptin levels in adolescents with primary hypertension Pediatr Nephrol 29 2014 423 429
43. T. Schoen, E.M. Hohmann, S. Van Der Lely, S. Aeschbacher, A. Reusser, M. Risch, and et al. Plasma copeptin levels and ambulatory blood pressure characteristics in healthy adults J Hypertens 33 8 2015 1571 1579 10.1097/HJH.0000000000000610
44. E. Zulfikaroglu, M. Islimye, E.A. Tonguc, A. Payasli, F. Isman, T. Var, and et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia J Obstet Gynaecol Res 37 2011 1198 1202
45. A.A. Foda, and I.A. Abdel Aal Maternal and neonatal copeptin levels at cesarean section and vaginal delivery Eur J Obstet Gynecol Reprod Biol 165 2012 215 218
46. S. Wellmann, J. Benzing, S. Fleischlin, N. Morgenthaler, S. Fouzas, C.A. Bührer, and et al. Cardiovascular biomarkers in preeclampsia at triage Fetal Diagn Ther 36 2014 202 207
47. M.K. Santillan, D.A. Santillan, S.M. Scroggins, J.Y. Min, J.A. Sandgren, N.A. Pearson, and et al. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model Hypertension 64 2014 852 859
48. E.H. Yeung, A. Liu, J.L. Mills, C. Zhang, T. Männistö, Z. Lu, and et al. Increased levels of copeptin before clinical diagnosis of preeclampsia Hypertension 64 2014 1362 1367
49. M. Katan, F. Fluri, N.G. Morgenthaler, P. Schuetz, C. Zweifel, R. Bingisser, and et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke Ann Neurol 66 2009 799 808
50. S.A. Urwyler, P. Schuetz, F. Fluri, N.G. Morgenthaler, C. Zweifel, A. Bergmann, and et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke Stroke 41 2010 1564 1567
51. J.L. Zhang, C.H. Yin, Y. Zhang, L.B. Zhao, H.J. Fu, and J.C. Feng Plasma copeptin and long-term outcomes in acute ischemic stroke Acta Neurol Scand 12 2013 372 380
52. M. Katan, N. Nigro, F. Fluri, P. Schuetz, N.G. Morgenthaler, F. Jax, and et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks Neurology 76 2011 563 566
53. G.M. De Marchis, A. Weck, H. Audebert, S. Benik, C. Foerch, D. Buhl, and et al. Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results from the CoRisk study Stroke 45 2014 2918 2923
54. C. Fung, G.M. De Marchis, M. Katan, M. Seiler, M. Arnold, J. Gralla, and et al. Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage PLOS ONE 8 2013 e53191
55. W.H. Yu, W.H. Wang, X.Q. Dong, Q. Du, D.B. Yang, Y.F. Shen, and et al. Prognostic significance of plasma copeptin detection compared with multiple biomarkers in intracerebral hemorrhage Clin Chim Acta 433 2014 174 178
56. F. Fluri, N.G. Morgenthaler, B. Mueller, M. Christ-Crain, and M. Katan Copeptin, procalcitonin and routine inflammatory markers - predictors of infection after stroke PLoS ONE 7 2012 e48309
57. S. Enhörning, T.J. Wang, P.M. Nilsson, P. Almgren, B. Hedblad, G. Berglund, and et al. Plasma copeptin and the risk of diabetes mellitus Circulation 121 2010 2102 2108
58. S. Enhörning, J. Struck, E. Wirfält, B. Hedblad, N.G. Morgenthaler, and O. Melander Plasma copeptin, a unifying factor behind the metabolic syndrome J Clin Endocrinol Metab 96 2011 E1065 E1072
59. S. Enhörning, B. Hedblad, P.M. Nilsson, G. Engström, and O. Melander Copeptin is an independent predictor of diabetic heart disease and death Am Heart J 169 4 2015 549 556.e1
60. I.J. Riphagen, W.E. Boertien, A. Alkhalaf, N. Kleefstra, R.T. Gansevoort, K.H. Groenier, and et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31) Diabetes Care 36 2013 3201 3207
61. C. Zellweger, K. Wildi, and R. Twerenbold Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction Int J Cardiol 190 2015 190 197
62. W.E. Boertien, I.J. Riphagen, I. Drion, A. Alkhalaf, S.J. Bakker, K.H. Groenier, and et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33) Diabetologia 56 2013 1680 1688
63. G. Velho, N. Bouby, S. Hadjadj, N. Matallah, K. Mohammedi, F. Fumeron, and et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria Diabetes Care 36 2013 3639 3645
64. D. Bar-Shalom, M.K. Poulsen, L.M. Rasmussen, A.C. Diederichsen, N.P. Sand, J.E. Henriksen, and et al. Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients Diab Vasc Dis Res 11 2014 448 450
65. B. Müller, N. Morgenthaler, D. Stolz, P. Schuetz, C. Müller, R. Bingisser, and et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections Eur J Clin Invest 37 2007 145 152
66. S. Krüger, J. Papassotiriou, R. Marre, K. Richter, C. Schumann, H. von Baum, and et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ Intensive Care Med 33 2007 2069 2078
67. S. Krüger, S. Ewig, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, and et al. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia - influence of antibiotic pre-treatment: results from the German competence network CAPNETZ J Antimicrob Chemother 64 2009 159 162
68. M. Kolditz, M. Halank, B. Schulte-Hubbert, S. Bergmann, S. Albrecht, and G. Höffken Copeptin predicts clinical deterioration and persistent instability in community acquired pneumonia Respir Med 106 2012 1320 1328
69. R. Seligman, J. Papassotiriou, N.G. Morgenthaler, M. Meisner, and P.J. Teixeira Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia Crit Care 12 2008 R11
70. R. Seligman, B.G. Seligman, and P.J. Teixeira Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia J Bras Pneumol 37 2011 495 503
71. L. Boeck, P. Eggimann, N. Smyrnios, H. Pargger, N. Thakkar, M. Siegemund, and et al. The Sequential Organ Failure Assessment score and copeptinfor predicting survival in ventilator-associated pneumonia J Crit Care 27 2012 523 e1-9
72. D. Stolz, M. Christ-Crain, N.G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, and et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD Chest 131 2007 1058 1067
73. O.T. Selcuk, M. Eyigor, L. Renda, U. Osma, H. Eyigor, N.T. Selcuk, and et al. Can we use serum copeptin levels as a biomarker in obstructive sleep apnea syndrome? J Craniomaxillofac Surg 43 2015 879 882
74. H. ÇInarka, S. Kayhan, M. Karataş, A. Yavuz, A. Gümüş, S. Özyurt, and et al. Copeptin: a new predictor for severe obstructive sleep apnea Ther Clin Risk Manag 11 2015 589 594
75. D.C. Akkoyun, A. Akyuz, F. Tulubas, N. AltIntas, S. Alpsoy, L.C. Mutlu, and et al. The serum copeptin levels in obstructive sleep apnea patients with prehypertensive Eur Rev Med Pharmacol Sci 19 9 2015 1721 1728 http://www.europeanreview.org/article/8899
76. W. Fenske, S. Störk, A. Blechschmidt, S.G. Maier, N.G. Morgenthaler, and B. Allolio Copeptin in the differential diagnosis of hyponatremia J Clin Endocrinol Metab 94 2009 123 129
77. N. Nigro, B. Müller, N.G. Morgenthaler, F. Fluri, P. Schuetz, S. Neiderta, and et al. The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases Swiss Med Wkly 141 October 2011 w13270 10.4414/smw.2011.13270
78. W. Fenske, M. Quinkler, D. Lorenz, K. Zopf, U. Haagen, J. Papassotiriou, and et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome - revisiting the direct and indirect water deprivation tests J Clin Endocrinol Metab 96 2011 1506 1515
79. M. Katan, N.G. Morgenthaler, K.C. Dixit, J. Rutishauser, G.E. Brabant, B. Müller, and et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay J Clin Endocrinol Metab 92 2007 2640 2643